Format

Send to

Choose Destination
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:411-428. doi: 10.1146/annurev-pharmtox-010617-052823. Epub 2017 Oct 6.

Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities.

Author information

1
Fishberg Department of Neuroscience and the Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; email: scott.russo@mssm.edu.

Abstract

Mood disorders such as depression are among the most prevalent psychiatric disorders in the United States, but they are inadequately treated in a substantial proportion of patients. Accordingly, neuropsychiatric research has pivoted from investigation of monoaminergic mechanisms to exploration of novel mediators, including the role of inflammatory processes. Subsets of mood disorder patients exhibit immune-related abnormalities, including elevated levels of proinflammatory cytokines, monocytes, and neutrophils in the peripheral circulation; dysregulation of neuroglia and blood-brain barrier function; and disruption of gut microbiota. The field of psychoneuroimmunology is one of great therapeutic opportunity, yielding experimental therapeutics for mood disorders, such as peripheral cytokine targeting antibodies, microglia and astrocyte targeting therapies, and probiotic treatments for gut dysbiosis, and producing findings that identify therapeutic targets for future development.

KEYWORDS:

inflammation; major depressive disorder; microbiome; mood disorders; therapeutics

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center